{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:04:21Z","timestamp":1740161061806,"version":"3.37.3"},"reference-count":230,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Appl Genetics"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s13353-024-00839-2","type":"journal-article","created":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:01:43Z","timestamp":1709942503000},"page":"705-726","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gene-edited cells: novel allogeneic gene\/cell therapy for epidermolysis bullosa"],"prefix":"10.1007","volume":"65","author":[{"given":"Fatemeh","family":"Gila","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vahab","family":"Alamdari-Palangi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maedeh","family":"Rafiee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arezoo","family":"Jokar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajad","family":"Ehtiaty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aria","family":"Dianatinasab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyyed Hossein","family":"Khatami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mortaza","family":"Taheri-Anganeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0576-4435","authenticated-orcid":false,"given":"Ahmad","family":"Movahedpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jafar","family":"Fallahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,9]]},"reference":[{"issue":"1","key":"839_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep11008","volume":"5","author":"E Aikawa","year":"2015","unstructured":"Aikawa E et al (2015) Systemic high-mobility group box 1 administration suppresses skin inflammation by inducing an accumulation of PDGFR\u03b1+ mesenchymal cells from bone marrow. Sci Rep 5(1):1\u201313","journal-title":"Sci Rep"},{"issue":"1","key":"839_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3109\/14653249.2010.518609","volume":"13","author":"V Alexeev","year":"2011","unstructured":"Alexeev V, Uitto J, Igoucheva O (2011) Gene expression signatures of mouse bone marrow-derived mesenchymal stem cells in the cutaneous environment and therapeutic implications for blistering skin disorder. Cytotherapy 13(1):30\u201345","journal-title":"Cytotherapy"},{"issue":"8","key":"839_CR3","first-page":"1","volume":"5","author":"G Alvin","year":"2021","unstructured":"Alvin G (2021) Cell therapy: the new approach to der-matology and dermatologic surgery. Clin Surg 5(8):1\u201314","journal-title":"Clin Surg"},{"key":"839_CR4","first-page":"61","volume":"14","author":"I Angelova-Fischer","year":"2005","unstructured":"Angelova-Fischer I et al (2005) Kindler syndrome: a case report and proposal for clinical diagnostic criteria. Acta Dermatovenerol Alp Panonica Adriat 14:61\u201367","journal-title":"Acta Dermatovenerol Alp Panonica Adriat"},{"key":"839_CR5","doi-asserted-by":"publisher","first-page":"113324","DOI":"10.1016\/j.biopha.2022.113324","volume":"153","author":"F Arabi","year":"2022","unstructured":"Arabi F, Mansouri V, Ahmadbeigi N (2022) Gene therapy clinical trials, where do we go? An overview. Biomed Pharmacother 153:113324","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"839_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00439-009-0646-5","volume":"125","author":"MJ Arin","year":"2009","unstructured":"Arin MJ (2009) The molecular basis of human keratin disorders. Hum Genet 125(4):355\u2013373","journal-title":"Hum Genet"},{"issue":"2","key":"839_CR7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1365-2230.2004.01465.x","volume":"29","author":"G Ashton","year":"2004","unstructured":"Ashton G (2004) Kindler syndrome. Clin Exp Dermatol 29(2):116\u2013121","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"839_CR8","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1046\/j.1365-2133.2001.04038.x","volume":"144","author":"G Ashton","year":"2001","unstructured":"Ashton G et al (2001) \u03b16\u03b24 integrin abnormalities in junctional epidermolysis bullosa with pyloric atresia. Br J Dermatol 144(2):408\u2013414","journal-title":"Br J Dermatol"},{"issue":"10","key":"839_CR9","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1038\/jid.2011.169","volume":"131","author":"SD Atkinson","year":"2011","unstructured":"Atkinson SD et al (2011) Development of allele-specific therapeutic siRNA for keratin 5 mutations in epidermolysis bullosa simplex. J Investig Dermatol 131(10):2079\u20132086","journal-title":"J Investig Dermatol"},{"issue":"5","key":"839_CR10","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.matbio.2005.05.006","volume":"24","author":"M Aumailley","year":"2005","unstructured":"Aumailley M et al (2005) A simplified laminin nomenclature. Matrix Biol 24(5):326\u2013332","journal-title":"Matrix Biol"},{"key":"839_CR11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.omtm.2017.06.008","volume":"6","author":"M Aushev","year":"2017","unstructured":"Aushev M et al (2017) Traceless targeting and isolation of gene-edited immortalized keratinocytes from epidermolysis bullosa simplex patients. Mol Ther Methods Clin Dev 6:112\u2013123","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"4","key":"839_CR12","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/jdv.17012","volume":"35","author":"R Baardman","year":"2021","unstructured":"Baardman R et al (2021) Novel insights into the epidemiology of epidermolysis bullosa (EB) from the Dutch EB Registry: EB more common than previously assumed? J Eur Acad Dermatol Venereol 35(4):995\u20131006","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"839_CR13","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1007\/s11033-020-05353-2","volume":"47","author":"CR Balistreri","year":"2020","unstructured":"Balistreri CR et al (2020) Stem cell therapy: old challenges and new solutions. Mol Biol Rep 47(4):3117\u20133131","journal-title":"Mol Biol Rep"},{"issue":"1","key":"839_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-020-0210-0","volume":"6","author":"A Bardhan","year":"2020","unstructured":"Bardhan A et al (2020) Epidermolysis bullosa. Nat Rev Dis Primers 6(1):1\u201327","journal-title":"Nat Rev Dis Primers"},{"key":"839_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/B978-0-12-410396-2.00008-6","volume-title":"Translational regenerative medicine","author":"RL Bartel","year":"2015","unstructured":"Bartel RL (2015) Stem cells and cell therapy: autologous cell manufacturing. In: Translational regenerative medicine. Elsevier, pp 107\u2013112"},{"issue":"1","key":"839_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s11658-019-0196-3","volume":"24","author":"R Bartoszewski","year":"2019","unstructured":"Bartoszewski R, Sikorski AF (2019) Editorial focus: understanding off-target effects as the key to successful RNAi therapy. Cell Mol Biol Lett 24(1):1\u201323","journal-title":"Cell Mol Biol Lett"},{"issue":"3","key":"839_CR17","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jid.2016.10.038","volume":"137","author":"J Bauer","year":"2017","unstructured":"Bauer J et al (2017) Closure of a large chronic wound through transplantation of gene-corrected epidermal stem cells. J Invest Dermatol 137(3):778\u2013781","journal-title":"J Invest Dermatol"},{"issue":"6","key":"839_CR18","first-page":"2099","volume":"101","author":"C Baum","year":"2003","unstructured":"Baum C et al (2003) Side effects of retroviral gene transfer into hematopoietic stem cells. Blood, J Am Soc Hematol 101(6):2099\u20132113","journal-title":"Blood, J Am Soc Hematol"},{"issue":"11","key":"839_CR19","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1016\/j.ymthe.2018.07.024","volume":"26","author":"D Benati","year":"2018","unstructured":"Benati D et al (2018) CRISPR\/Cas9-mediated in situ correction of LAMB3 gene in keratinocytes derived from a junctional epidermolysis bullosa patient. Mol Ther 26(11):2592\u20132603","journal-title":"Mol Ther"},{"key":"839_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","volume":"50","author":"CF Bennett","year":"2010","unstructured":"Bennett CF, Swayze EE (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50:259\u2013293","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"839_CR21","first-page":"637","volume":"164","author":"M Bolling","year":"2011","unstructured":"Bolling M et al (2011) Mutations in KRT5 and KRT14 cause epidermolysis bullosa simplex in 75% of the patients. Br J Dermatol 164(3):637\u2013644","journal-title":"Br J Dermatol"},{"issue":"8","key":"839_CR22","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.3390\/cells10081992","volume":"10","author":"G Bonaventura","year":"2021","unstructured":"Bonaventura G et al (2021) Stem cells: innovative therapeutic options for neurodegenerative diseases? Cells 10(8):1992","journal-title":"Cells"},{"issue":"8","key":"839_CR23","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.drudis.2019.05.038","volume":"24","author":"T Bordet","year":"2019","unstructured":"Bordet T, Behar-Cohen F (2019) Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives. Drug Discov Today 24(8):1685\u20131693","journal-title":"Drug Discov Today"},{"issue":"12","key":"839_CR24","first-page":"1110","volume":"84","author":"C Bordignon","year":"1999","unstructured":"Bordignon C et al (1999) Cell therapy: achievements and perspectives. Haematologica 84(12):1110\u20131149","journal-title":"Haematologica"},{"issue":"7","key":"839_CR25","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/mt.2016.92","volume":"24","author":"O Bornert","year":"2016","unstructured":"Bornert O et al (2016) Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy. Mol Ther 24(7):1302\u20131311","journal-title":"Mol Ther"},{"issue":"4","key":"839_CR26","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.jid.2020.08.018","volume":"141","author":"O Bornert","year":"2021","unstructured":"Bornert O et al (2021) QR-313, an antisense oligonucleotide, shows therapeutic efficacy for treatment of dominant and recessive dystrophic epidermolysis bullosa: a preclinical study. J Investig Dermatol 141(4):883\u2013893","journal-title":"J Investig Dermatol"},{"key":"839_CR27","doi-asserted-by":"crossref","unstructured":"Bremer J et al (2016) Antisense oligonucleotide-mediated exon skipping as a systemic therapeutic approach for recessive dystrophic epidermolysis bullosa. Mol Ther Nucleic Acids:5","DOI":"10.1038\/mtna.2016.87"},{"issue":"1","key":"839_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-019-1279-y","volume":"15","author":"AL Bruckner","year":"2020","unstructured":"Bruckner AL et al (2020) The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers. Orphanet J Rare Dis 15(1):1\u201314","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"839_CR29","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/jid.2013.127","volume":"133","author":"L Bruckner-Tuderman","year":"2013","unstructured":"Bruckner-Tuderman L et al (2013) Progress in epidermolysis bullosa research: summary of DEBRA International Research Conference 2012. J Investig Dermatol 133(9):2121\u20132126","journal-title":"J Investig Dermatol"},{"issue":"2","key":"839_CR30","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S0190-9622(87)70199-6","volume":"17","author":"DM Carter","year":"1987","unstructured":"Carter DM et al (1987) Treatment of junctional epidermolysis bullosa with epidermal autografts. J Am Acad Dermatol 17(2):246\u2013250","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"839_CR31","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2353\/ajpath.2008.070977","volume":"173","author":"T Chino","year":"2008","unstructured":"Chino T et al (2008) Bone marrow cell transfer into fetal circulation can ameliorate genetic skin diseases by providing fibroblasts to the skin and inducing immune tolerance. Am J Pathol 173(3):803\u2013814","journal-title":"Am J Pathol"},{"issue":"32","key":"839_CR32","doi-asserted-by":"publisher","first-page":"20256","DOI":"10.1016\/S0021-9258(17)31984-1","volume":"269","author":"AM Christiano","year":"1994","unstructured":"Christiano AM et al (1994) Cloning of human type VII collagen. Complete primary sequence of the alpha 1 (VII) chain and identification of intragenic polymorphisms. J Biol Chem 269(32):20256\u201320262","journal-title":"J Biol Chem"},{"issue":"10","key":"839_CR33","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1038\/mt.2014.140","volume":"22","author":"J Cogan","year":"2014","unstructured":"Cogan J et al (2014) Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa. Mol Ther 22(10):1741\u20131752","journal-title":"Mol Ther"},{"issue":"9","key":"839_CR34","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1038\/mt.2013.143","volume":"21","author":"A Coluccio","year":"2013","unstructured":"Coluccio A et al (2013) Targeted gene addition in human epithelial stem cells by zinc-finger nuclease-mediated homologous recombination. Mol Ther 21(9):1695\u20131704","journal-title":"Mol Ther"},{"key":"839_CR35","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3389\/fmed.2018.00363","volume":"5","author":"I Condrat","year":"2019","unstructured":"Condrat I et al (2019) Junctional epidermolysis bullosa: allelic heterogeneity and mutation stratification for precision medicine. Front Med 5:363","journal-title":"Front Med"},{"issue":"6121","key":"839_CR36","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong L et al (2013) Multiplex genome engineering using CRISPR\/Cas systems. Science 339(6121):819\u2013823","journal-title":"Science"},{"issue":"3","key":"839_CR37","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3109\/14653241003587637","volume":"12","author":"P Conget","year":"2010","unstructured":"Conget P et al (2010) Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa. Cytotherapy 12(3):429\u2013431","journal-title":"Cytotherapy"},{"issue":"7","key":"839_CR38","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1172\/JCI38177","volume":"119","author":"PA Coulombe","year":"2009","unstructured":"Coulombe PA, Kerns ML, Fuchs E (2009) Epidermolysis bullosa simplex: a paradigm for disorders of tissue fragility. J Clin Invest 119(7):1784\u20131793","journal-title":"J Clin Invest"},{"issue":"1","key":"839_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/exd.12246","volume":"23","author":"L Cutlar","year":"2014","unstructured":"Cutlar L, Greiser U, Wang W (2014) Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa. Exp Dermatol 23(1):1\u20136","journal-title":"Exp Dermatol"},{"issue":"7","key":"839_CR40","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/j.1600-0625.2008.00723.x","volume":"17","author":"N Dang","year":"2008","unstructured":"Dang N, Murrell DF (2008) Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa. Exp Dermatol 17(7):553\u2013568","journal-title":"Exp Dermatol"},{"issue":"1","key":"839_CR41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/sj.jp.7211019","volume":"24","author":"BB Das","year":"2004","unstructured":"Das BB, Sahoo S (2004) Dystrophic epidermolysis bullosa. J Perinatol 24(1):41\u201347","journal-title":"J Perinatol"},{"issue":"2","key":"839_CR42","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/bjd.15896","volume":"178","author":"B Dasgeb","year":"2018","unstructured":"Dasgeb B et al (2018) Colchicine: an ancient drug with novel applications. Br J Dermatol 178(2):350\u2013356","journal-title":"Br J Dermatol"},{"issue":"7","key":"839_CR43","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41556-019-0344-z","volume":"21","author":"M De Luca","year":"2019","unstructured":"De Luca M et al (2019) Advances in stem cell research and therapeutic development. Nat Cell Biol 21(7):801\u2013811","journal-title":"Nat Cell Biol"},{"issue":"5","key":"839_CR44","doi-asserted-by":"publisher","first-page":"a035667","DOI":"10.1101\/cshperspect.a035667","volume":"12","author":"L De Rosa","year":"2020","unstructured":"De Rosa L et al (2020) Toward combined cell and gene therapy for genodermatoses. Cold Spring Harb Perspect Biol 12(5):a035667","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"5","key":"839_CR45","first-page":"347","volume":"1","author":"N Dias","year":"2002","unstructured":"Dias N, Stein C (2002) Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 1(5):347\u2013355","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"839_CR46","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M et al (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4):315\u2013317","journal-title":"Cytotherapy"},{"issue":"2","key":"839_CR47","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.det.2009.12.001","volume":"28","author":"R Eady","year":"2010","unstructured":"Eady R, Dopping-Hepenstal (2010) Transmission electron microscopy for the diagnosis of epidermolysis bullosa. Dermatol Clin 28(2):211\u2013222","journal-title":"Dermatol Clin"},{"issue":"6","key":"839_CR48","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/bjd.17858","volume":"181","author":"C Ebens","year":"2019","unstructured":"Ebens C et al (2019) Bone marrow transplant with post-transplant cyclophosphamide for recessive dystrophic epidermolysis bullosa expands the related donor pool and permits tolerance of nonhaematopoietic cellular grafts. Br J Dermatol 181(6):1238\u20131246","journal-title":"Br J Dermatol"},{"key":"839_CR49","doi-asserted-by":"crossref","unstructured":"Eichstadt S et al (2019a) Phase 1\/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa. JCI insight 4(19)","DOI":"10.1172\/jci.insight.130554"},{"key":"839_CR50","doi-asserted-by":"crossref","unstructured":"Eichstadt S et al (2019b) Phase 1\/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa. JCI. Insight 4(19)","DOI":"10.1172\/jci.insight.130554"},{"issue":"10","key":"839_CR51","doi-asserted-by":"publisher","first-page":"520","DOI":"10.5694\/j.1326-5377.1987.tb133652.x","volume":"147","author":"M Eisenberg","year":"1987","unstructured":"Eisenberg M et al (1987) Successful engraftment of cultured human epidermal allograft in a child with recessive dystrophic epidermolysis bullosa. Med J Aust 147(10):520\u2013521","journal-title":"Med J Aust"},{"issue":"3","key":"839_CR52","doi-asserted-by":"publisher","first-page":"99","DOI":"10.52547\/wjps.10.3.99","volume":"10","author":"S Farokhforghani","year":"2021","unstructured":"Farokhforghani S et al (2021) Epidermolysis bullosa registry data in Iran. World J Plast Surg 10(3):99","journal-title":"World J Plast Surg"},{"issue":"1","key":"839_CR53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1385\/MB:22:1:025","volume":"22","author":"KA Felts","year":"2002","unstructured":"Felts KA et al (2002) Functional cloning using pFB retroviral cDNA expression libraries. Mol Biotechnol 22(1):25\u201332","journal-title":"Mol Biotechnol"},{"issue":"1","key":"839_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-5-12","volume":"5","author":"J-D Fine","year":"2010","unstructured":"Fine J-D (2010) Inherited epidermolysis bullosa. Orphanet J Rare Dis 5(1):1\u201317","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"839_CR55","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jamadermatol.2016.2473","volume":"152","author":"J-D Fine","year":"2016","unstructured":"Fine J-D (2016) Epidemiology of inherited epidermolysis bullosa based on incidence and prevalence estimates from the National Epidermolysis Bullosa Registry. JAMA Dermatol 152(11):1231\u20131238","journal-title":"JAMA Dermatol"},{"issue":"1","key":"839_CR56","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0190-9622(91)70021-S","volume":"24","author":"J-D Fine","year":"1991","unstructured":"Fine J-D et al (1991) Revised clinical and laboratory criteria for subtypes of inherited epidermolysis bullosa: a consensus report by the subcommittee on diagnosis and classification of the National Epidermolysis Bullosa Registry. J Am Acad Dermatol 24(1):119\u2013135","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"839_CR57","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jaad.2008.02.004","volume":"58","author":"J-D Fine","year":"2008","unstructured":"Fine J-D et al (2008) The classification of inherited epidermolysis bullosa (EB): report of the third international consensus meeting on diagnosis and classification of EB. J Am Acad Dermatol 58(6):931\u2013950","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"839_CR58","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.jaad.2014.01.903","volume":"70","author":"J-D Fine","year":"2014","unstructured":"Fine J-D et al (2014) Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol 70(6):1103\u20131126","journal-title":"J Am Acad Dermatol"},{"key":"839_CR59","unstructured":"Firing C, Bygum A (2017) Epidermolysis bullosa. Ugeskr Laeger 179(47)"},{"issue":"1","key":"839_CR60","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1046\/j.0022-202X.2003.22125.x","volume":"122","author":"L Fontao","year":"2004","unstructured":"Fontao L et al (2004) Molecular consequences of deletion of the cytoplasmic domain of bullous pemphigoid 180 in a patient with predominant features of epidermolysis bullosa simplex. J Investig Dermatol 122(1):65\u201372","journal-title":"J Investig Dermatol"},{"issue":"4","key":"839_CR61","doi-asserted-by":"publisher","first-page":"244","DOI":"10.12968\/bjon.2007.16.4.22993","volume":"16","author":"L Foster","year":"2007","unstructured":"Foster L, Holmes Y (2007) Transition from paediatric to adult service in epidermolysis bullosa. Br J Nurs 16(4):244\u2013246","journal-title":"Br J Nurs"},{"issue":"3","key":"839_CR62","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3390\/ijms21030777","volume":"21","author":"LE Fry","year":"2020","unstructured":"Fry LE et al (2020) RNA editing as a therapeutic approach for retinal gene therapy requiring long coding sequences. Int J Mol Sci 21(3):777","journal-title":"Int J Mol Sci"},{"issue":"8","key":"839_CR63","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1111\/jdv.17201","volume":"35","author":"Y Fujita","year":"2021","unstructured":"Fujita Y et al (2021) Intravenous allogeneic multilineage-differentiating stress-enduring cells in adults with dystrophic epidermolysis bullosa: a phase 1\/2 open-label study. J Eur Acad Dermatol Venereol 35(8):e528","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"839_CR64","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1056\/NEJM198408163110706","volume":"311","author":"GG Gallico III","year":"1984","unstructured":"Gallico GG III et al (1984) Permanent coverage of large burn wounds with autologous cultured human epithelium. N Engl J Med 311(7):448\u2013451","journal-title":"N Engl J Med"},{"issue":"1","key":"839_CR65","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/ajd.13762","volume":"63","author":"R Gear","year":"2022","unstructured":"Gear R et al (2022) Epidemiological, clinical, pathological and genetic characteristics of epidermolysis bullosa in New Zealand. Australas J Dermatol 63(1):62\u201367","journal-title":"Australas J Dermatol"},{"issue":"1","key":"839_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-014-0178-2","volume":"12","author":"KR Goldschneider","year":"2014","unstructured":"Goldschneider KR et al (2014) Pain care for patients with epidermolysis bullosa: best care practice guidelines. BMC Med 12(1):1\u201323","journal-title":"BMC Med"},{"issue":"3","key":"839_CR67","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2340\/00015555-3097","volume":"99","author":"KB Gosty\u0144ska","year":"2019","unstructured":"Gosty\u0144ska KB et al (2019) Allogeneic haematopoietic cell transplantation for epidermolysis bullosa: the Dutch experience. Acta Derm Venereol 99(3):347\u2013348","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"839_CR68","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1038\/sj.jid.5700435","volume":"126","author":"M Goto","year":"2006","unstructured":"Goto M et al (2006) Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients. J Investig Dermatol 126(12):2614\u20132620","journal-title":"J Investig Dermatol"},{"issue":"11","key":"839_CR69","doi-asserted-by":"publisher","first-page":"5665","DOI":"10.1073\/pnas.76.11.5665","volume":"76","author":"H Green","year":"1979","unstructured":"Green H, Kehinde O, Thomas J (1979) Growth of cultured human epidermal cells into multiple epithelia suitable for grafting. Proc Natl Acad Sci 76(11):5665\u20135668","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"839_CR70","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/trf.16814","volume":"62","author":"I Guleria","year":"2022","unstructured":"Guleria I et al (2022) How do I: evaluate the safety and legitimacy of unproven cellular therapies? Transfusion 62(3):518\u2013532","journal-title":"Transfusion"},{"key":"839_CR71","doi-asserted-by":"publisher","first-page":"1143157","DOI":"10.3389\/fbioe.2023.1143157","volume":"11","author":"C Guo","year":"2023","unstructured":"Guo C et al (2023) Off-target effects in CRISPR\/Cas9 gene editing. Front Bioeng Biotechnol 11:1143157","journal-title":"Front Bioeng Biotechnol"},{"issue":"4","key":"839_CR72","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41591-022-01737-y","volume":"28","author":"I Gurevich","year":"2022","unstructured":"Gurevich I et al (2022) In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. Nat Med 28(4):780\u2013788","journal-title":"Nat Med"},{"issue":"3","key":"839_CR73","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.4049\/jimmunol.179.3.1595","volume":"179","author":"MA Haniffa","year":"2007","unstructured":"Haniffa MA et al (2007) Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol 179(3):1595\u20131604","journal-title":"J Immunol"},{"issue":"2","key":"839_CR74","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3324\/haematol.13699","volume":"94","author":"MA Haniffa","year":"2009","unstructured":"Haniffa MA et al (2009) Mesenchymal stem cells: the fibroblasts\u2019 new clothes? Haematologica 94(2):258\u2013263","journal-title":"Haematologica"},{"issue":"6","key":"839_CR75","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.jid.2017.02.011","volume":"137","author":"C Has","year":"2017","unstructured":"Has C (2017) The \u201cKelch\u201d surprise: KLHL24, a new player in the pathogenesis of skin fragility. J Investig Dermatol 137(6):1211\u20131212","journal-title":"J Investig Dermatol"},{"issue":"3","key":"839_CR76","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40291-020-00466-7","volume":"24","author":"C Has","year":"2020","unstructured":"Has C, South A, Uitto J (2020b) Molecular therapeutics in development for epidermolysis bullosa: update 2020. Mol Diagn Ther 24(3):299\u2013309","journal-title":"Mol Diagn Ther"},{"key":"839_CR77","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.matbio.2018.04.001","volume":"71","author":"C Has","year":"2018","unstructured":"Has C et al (2018) Epidermolysis bullosa: molecular pathology of connective tissue components in the cutaneous basement membrane zone. Matrix Biol 71:313\u2013329","journal-title":"Matrix Biol"},{"issue":"4","key":"839_CR78","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bjd.18921","volume":"183","author":"C Has","year":"2020","unstructured":"Has C et al (2020a) Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol 183(4):614\u2013627","journal-title":"Br J Dermatol"},{"issue":"16","key":"839_CR79","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1007\/s00018-012-1204-1","volume":"70","author":"J Hauschild-Quintern","year":"2013","unstructured":"Hauschild-Quintern J et al (2013) Gene knockout and knockin by zinc-finger nucleases: current status and perspectives. Cell Mol Life Sci 70(16):2969\u20132983","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"839_CR80","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1365-2133.1987.tb04132.x","volume":"117","author":"A Heagerty","year":"1987","unstructured":"Heagerty A et al (1987) Rapid prenatal diagnosis of epidermolysis bullosa letalis using GB3 monoclonal antibody. Br J Dermatol 117(3):271\u2013275","journal-title":"Br J Dermatol"},{"issue":"47","key":"839_CR81","doi-asserted-by":"publisher","first-page":"36082","DOI":"10.1074\/jbc.M606259200","volume":"281","author":"C Herz","year":"2006","unstructured":"Herz C et al (2006) Kindlin-1 is a phosphoprotein involved in regulation of polarity, proliferation, and motility of epidermal keratinocytes. J Biol Chem 281(47):36082\u201336090","journal-title":"J Biol Chem"},{"issue":"7680","key":"839_CR82","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature24487","volume":"551","author":"T Hirsch","year":"2017","unstructured":"Hirsch T et al (2017) Regeneration of the entire human epidermis using transgenic stem cells. Nature 551(7680):327\u2013332","journal-title":"Nature"},{"key":"839_CR83","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s40257-021-00626-3","volume":"22","author":"P-C Hou","year":"2021","unstructured":"Hou P-C et al (2021) Investigational treatments for epidermolysis bullosa. Am J Clin Dermatol 22:801\u2013817","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"839_CR84","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1038\/jid.2015.291","volume":"135","author":"Y Hou","year":"2015","unstructured":"Hou Y et al (2015) Intravenously administered recombinant human type VII collagen derived from Chinese hamster ovary cells reverses the disease phenotype in recessive dystrophic epidermolysis bullosa mice. J Investig Dermatol 135(12):3060\u20133067","journal-title":"J Investig Dermatol"},{"key":"839_CR85","unstructured":"Hourd P et al (2021) Regulatory challenges for the manufacture and scale-out of autologous cell therapies. Int J Biomed Health Sci 10(4)"},{"issue":"3","key":"839_CR86","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/exd.12084","volume":"22","author":"C H\u00fcnefeld","year":"2013","unstructured":"H\u00fcnefeld C et al (2013) One goal, different strategies\u2013molecular and cellular approaches for the treatment of inherited skin fragility disorders. Exp Dermatol 22(3):162\u2013167","journal-title":"Exp Dermatol"},{"issue":"6","key":"839_CR87","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.2353\/ajpath.2009.090347","volume":"175","author":"K Ito","year":"2009","unstructured":"Ito K et al (2009) Keratinocyte-\/fibroblast-targeted rescue of Col7a1-disrupted mice and generation of an exact dystrophic epidermolysis bullosa model using a human COL7A1 mutation. Am J Pathol 175(6):2508\u20132517","journal-title":"Am J Pathol"},{"issue":"12","key":"839_CR88","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1089\/scd.2014.0568","volume":"24","author":"H Kaipe","year":"2015","unstructured":"Kaipe H et al (2015) Immunogenicity of decidual stromal cells in an epidermolysis bullosa patient and in allogeneic hematopoietic stem cell transplantation patients. Stem Cells Dev 24(12):1471\u20131482","journal-title":"Stem Cells Dev"},{"issue":"1","key":"839_CR89","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1096\/fj.201801059","volume":"33","author":"O Kashpur","year":"2019","unstructured":"Kashpur O et al (2019) Differentiation of diabetic foot ulcer\u2013derived induced pluripotent stem cells reveals distinct cellular and tissue phenotypes. FASEB J 33(1):1262\u20131277","journal-title":"FASEB J"},{"key":"839_CR90","doi-asserted-by":"publisher","first-page":"348","DOI":"10.4103\/0378-6323.16788","volume":"71","author":"P Kaviarasan","year":"2005","unstructured":"Kaviarasan P, Prasad PV, Shradda PV (2005) Kindler syndrome. Indian J Dermatol Venereol Leprol 71:348","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"9","key":"839_CR91","first-page":"234","volume":"21","author":"B Kazmi","year":"2009","unstructured":"Kazmi B, Inglefield CJ, Lewis M (2009) Autologous cell therapy: current treatments and future prospects. Wounds 21(9):234\u2013242","journal-title":"Wounds"},{"issue":"8","key":"839_CR92","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1080\/14712598.2020.1740678","volume":"20","author":"AR Keith","year":"2020","unstructured":"Keith AR et al (2020) Leading edge: emerging drug, cell, and gene therapies for junctional epidermolysis bullosa. Expert Opin Biol Ther 20(8):911\u2013923","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"839_CR93","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/mt.2009.144","volume":"17","author":"JS Kern","year":"2009","unstructured":"Kern JS et al (2009) Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity. Mol Ther 17(9):1605\u20131615","journal-title":"Mol Ther"},{"issue":"5","key":"839_CR94","first-page":"582","volume":"45","author":"MS Khaniani","year":"2015","unstructured":"Khaniani MS et al (2015) One novel frameshift mutation on exon 64 of COL7A1 gene in an Iranian individual suffering recessive dystrophic epidermolysis bullosa. Ann Clin Lab Sci 45(5):582\u2013584","journal-title":"Ann Clin Lab Sci"},{"issue":"6","key":"839_CR95","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/archdermatol.2010.109","volume":"146","author":"YC Kho","year":"2010","unstructured":"Kho YC et al (2010) Epidemiology of epidermolysis bullosa in the antipodes: the Australasian Epidermolysis Bullosa Registry with a focus on Herlitz junctional epidermolysis bullosa. Arch Dermatol 146(6):635\u2013640","journal-title":"Arch Dermatol"},{"issue":"7","key":"839_CR96","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1136\/jmg.2010.086751","volume":"48","author":"D Kiritsi","year":"2011","unstructured":"Kiritsi D et al (2011) Molecular mechanisms of phenotypic variability in junctional epidermolysis bullosa. J Med Genet 48(7):450\u2013457","journal-title":"J Med Genet"},{"issue":"4","key":"839_CR97","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/pde.12018","volume":"31","author":"A Kittridge","year":"2014","unstructured":"Kittridge A et al (2014) Herlitz junctional epidermolysis bullosa with a novel mutation in LAMB 3. Pediatr Dermatol 31(4):530\u2013532","journal-title":"Pediatr Dermatol"},{"issue":"22","key":"839_CR98","doi-asserted-by":"publisher","first-page":"17975","DOI":"10.1074\/jbc.M111.310458","volume":"287","author":"KR Kligys","year":"2012","unstructured":"Kligys KR et al (2012) \u03b16\u03b24 integrin, a master regulator of expression of integrins in human keratinocytes. J Biol Chem 287(22):17975\u201317984","journal-title":"J Biol Chem"},{"key":"839_CR99","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/bs.pmbts.2020.12.007","volume":"182","author":"T Kocher","year":"2021","unstructured":"Kocher T, Koller U (2021) Advances in gene editing strategies for epidermolysis bullosa. Prog Mol Biol Transl Sci 182:81\u2013109","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"11","key":"839_CR100","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1016\/j.ymthe.2017.08.015","volume":"25","author":"T Kocher","year":"2017","unstructured":"Kocher T et al (2017) Cut and paste: efficient homology-directed repair of a dominant negative KRT14 mutation via CRISPR\/Cas9 nickases. Mol Ther 25(11):2585\u20132598","journal-title":"Mol Ther"},{"key":"839_CR101","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.omtn.2019.09.011","volume":"18","author":"T Kocher","year":"2019","unstructured":"Kocher T et al (2019) Improved double-nicking strategies for COL7A1-editing by homologous recombination. Mol Ther Nucleic Acids 18:496\u2013507","journal-title":"Mol Ther Nucleic Acids"},{"issue":"10","key":"839_CR102","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1016\/j.jid.2020.02.012","volume":"140","author":"T Kocher","year":"2020","unstructured":"Kocher T et al (2020) Predictable CRISPR\/Cas9-mediated COL7A1 reframing for dystrophic epidermolysis bullosa. J Investig Dermatol 140(10):1985\u20131993","journal-title":"J Investig Dermatol"},{"key":"839_CR103","doi-asserted-by":"crossref","unstructured":"Koller U et al (2014) Considerations for a successful RNA trans-splicing repair of genetic disorders. Mol Ther Nucleic Acids:3","DOI":"10.1038\/mtna.2014.10"},{"issue":"2","key":"839_CR104","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/01.TP.0000144325.01925.BE","volume":"79","author":"J Kopp","year":"2005","unstructured":"Kopp J et al (2005) Hematopoietic stem cell transplantation and subsequent 80% skin exchange by grafts from the same donor in a patient with Herlitz disease. Transplantation 79(2):255\u2013256","journal-title":"Transplantation"},{"issue":"6","key":"839_CR105","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","volume":"16","author":"JA Kulkarni","year":"2021","unstructured":"Kulkarni JA et al (2021) The current landscape of nucleic acid therapeutics. Nat Nanotechnol 16(6):630\u2013643","journal-title":"Nat Nanotechnol"},{"issue":"12","key":"839_CR106","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.3390\/cells10123278","volume":"10","author":"M Kulus","year":"2021","unstructured":"Kulus M et al (2021) Mesenchymal stem\/stromal cells derived from human and animal perinatal tissues\u2014origins, characteristics, signaling pathways, and clinical trials. Cells 10(12):3278","journal-title":"Cells"},{"issue":"12","key":"839_CR107","first-page":"38","volume":"7","author":"S Kumar","year":"2014","unstructured":"Kumar S et al (2014) Autologous therapies in dermatology. J Clin Aesthet Dermatol 7(12):38","journal-title":"J Clin Aesthet Dermatol"},{"issue":"2","key":"839_CR108","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1365-2133.2008.08976.x","volume":"160","author":"J Lai-Cheong","year":"2009","unstructured":"Lai-Cheong J et al (2009a) Kindler syndrome: a focal adhesion genodermatosis. Br J Dermatol 160(2):233\u2013242","journal-title":"Br J Dermatol"},{"issue":"1","key":"839_CR109","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.det.2009.10.013","volume":"28","author":"JE Lai-Cheong","year":"2010","unstructured":"Lai-Cheong JE, McGrath JA (2010) Kindler syndrome. Dermatol Clin 28(1):119\u2013124","journal-title":"Dermatol Clin"},{"issue":"4","key":"839_CR110","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.2353\/ajpath.2009.081154","volume":"175","author":"JE Lai-Cheong","year":"2009","unstructured":"Lai-Cheong JE et al (2009b) Loss-of-function FERMT1 mutations in kindler syndrome implicate a role for fermitin family homolog-1 in integrin activation. Am J Pathol 175(4):1431\u20131441","journal-title":"Am J Pathol"},{"issue":"4","key":"839_CR111","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/path.1643","volume":"204","author":"E Lane","year":"2004","unstructured":"Lane E, McLean W (2004) Keratins and skin disorders. J Pathol: A J Pathol Soc Great Britain and Ireland 204(4):355\u2013366","journal-title":"J Pathol: A J Pathol Soc Great Britain and Ireland"},{"issue":"7","key":"839_CR112","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1089\/wound.2017.0761","volume":"7","author":"J Larouche","year":"2018","unstructured":"Larouche J et al (2018) Immune regulation of skin wound healing: mechanisms and novel therapeutic targets. Adv Wound Care 7(7):209\u2013231","journal-title":"Adv Wound Care"},{"issue":"4","key":"839_CR113","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.jid.2016.11.038","volume":"137","author":"MC Latella","year":"2017","unstructured":"Latella MC et al (2017) Correction of recessive dystrophic epidermolysis bullosa by transposon-mediated integration of COL7A1 in transplantable patient-derived primary keratinocytes. J Investig Dermatol 137(4):836\u2013844","journal-title":"J Investig Dermatol"},{"key":"839_CR114","doi-asserted-by":"crossref","unstructured":"Lee SE et al (2021) Intravenous allogeneic umbilical cord blood\u2013derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients. JCI insight 6(2)","DOI":"10.1172\/jci.insight.143606"},{"issue":"1-3","key":"839_CR115","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0169-409X(97)00102-6","volume":"30","author":"P Lehn","year":"1998","unstructured":"Lehn P et al (1998) Gene delivery systems: bridging the gap between recombinant viruses and artificial vectors. Adv Drug Deliv Rev 30(1-3):5\u201311","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"839_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2045-3701-3-21","volume":"3","author":"Y Lei","year":"2013","unstructured":"Lei Y et al (2013) Generation of gene disruptions by transcription activator-like effector nucleases (TALENs) in Xenopus tropicalis embryos. Cell Biosci 3(1):1\u201310","journal-title":"Cell Biosci"},{"key":"839_CR117","doi-asserted-by":"crossref","unstructured":"Lukomska B et al (2019) Challenges and controversies in human mesenchymal stem cell therapy. Stem Cells Int 2019","DOI":"10.1155\/2019\/9628536"},{"issue":"1","key":"839_CR118","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3390\/cells9010112","volume":"9","author":"OP March","year":"2020","unstructured":"March OP, Kocher T, Koller U (2020) Context-dependent strategies for enhanced genome editing of genodermatoses. Cells 9(1):112","journal-title":"Cells"},{"key":"839_CR119","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.abd.2020.05.001","volume":"95","author":"LM Mariath","year":"2020","unstructured":"Mariath LM et al (2020) Inherited epidermolysis bullosa: update on the clinical and genetic aspects. An Bras Dermatol 95:551\u2013569","journal-title":"An Bras Dermatol"},{"key":"839_CR120","first-page":"505","volume-title":"Epidermolysis bullosa. Fitzpatrick\u2019s dermatology in general medicine","author":"MP Marinkovich","year":"2008","unstructured":"Marinkovich MP, Bauer E (2008) Epidermolysis bullosa. Fitzpatrick\u2019s dermatology in general medicine, 7th edn. McGraw-Hill, New York, pp 505\u2013516","edition":"7"},{"issue":"6","key":"839_CR121","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.jid.2018.11.036","volume":"139","author":"MP Marinkovich","year":"2019","unstructured":"Marinkovich MP, Tang JY (2019) Gene therapy for epidermolysis bullosa. J Investig Dermatol 139(6):1221\u20131226","journal-title":"J Investig Dermatol"},{"key":"839_CR122","doi-asserted-by":"publisher","first-page":"576558","DOI":"10.3389\/fmed.2020.576558","volume":"7","author":"R Maseda","year":"2020","unstructured":"Maseda R et al (2020) Beneficial effect of systemic allogeneic adipose derived mesenchymal cells on the clinical, inflammatory and immunologic status of a patient with recessive dystrophic epidermolysis bullosa: a case report. Front Med 7:576558","journal-title":"Front Med"},{"issue":"2","key":"839_CR123","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/TP.0000000000000204","volume":"98","author":"DW Mathes","year":"2014","unstructured":"Mathes DW et al (2014) Simultaneous transplantation of hematopoietic stem cells and a vascularized composite allograft leads to tolerance. Transplantation 98(2):131","journal-title":"Transplantation"},{"issue":"12","key":"839_CR124","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/nm1504","volume":"12","author":"F Mavilio","year":"2006","unstructured":"Mavilio F et al (2006) Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med 12(12):1397\u20131402","journal-title":"Nat Med"},{"issue":"6 Suppl","key":"839_CR125","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2217\/rme.12.83","volume":"7","author":"TN McAllister","year":"2012","unstructured":"McAllister TN, Audley D, L\u2019Heureux N (2012) Autologous cell therapies: challenges in US FDA regulation. Regen Med 7(6 Suppl):94\u201397","journal-title":"Regen Med"},{"key":"839_CR126","first-page":"3.2-3.80","volume":"1","author":"J McGrath","year":"2004","unstructured":"McGrath J, Eady R, Pope F (2004) Anatomy and organization of human skin. Rook\u2019s Textbook Dermatol 1:3.2-3.80","journal-title":"Rook\u2019s Textbook Dermatol"},{"issue":"3","key":"839_CR127","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0190-9622(93)70203-6","volume":"29","author":"JA McGrath","year":"1993","unstructured":"McGrath JA et al (1993) Cultured keratinocyte allografts and wound healing in severe recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol 29(3):407\u2013419","journal-title":"J Am Acad Dermatol"},{"key":"839_CR128","volume-title":"Journal of Investigative Dermatology Symposium Proceedings","author":"WI McLean","year":"2005","unstructured":"McLean WI, Smith FJ, Cassidy AJ (2005) Insights into genotype\u2013phenotype correlation in pachyonychia congenita from the human intermediate filament mutation database. In: Journal of Investigative Dermatology Symposium Proceedings. Elsevier"},{"issue":"4","key":"839_CR129","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/mt.2013.290","volume":"22","author":"SP Melo","year":"2014","unstructured":"Melo SP et al (2014) Somatic correction of junctional epidermolysis bullosa by a highly recombinogenic AAV variant. Mol Ther 22(4):725\u2013733","journal-title":"Mol Ther"},{"key":"839_CR130","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.omtn.2018.01.009","volume":"11","author":"\u00c1 Menc\u00eda","year":"2018","unstructured":"Menc\u00eda \u00c1 et al (2018) Deletion of a pathogenic mutation-containing exon of COL7A1 allows clonal gene editing correction of RDEB patient epidermal stem cells. Mol Ther Nucleic Acids 11:68\u201378","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"839_CR131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12876-018-0771-5","volume":"18","author":"A Michalak","year":"2018","unstructured":"Michalak A et al (2018) A rare case of skin blistering and esophageal stenosis in the course of epidermolysis bullosa-case report and literature review. BMC Gastroenterol 18(1):1\u20135","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"839_CR132","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1097\/BCR.0b013e31825aeac1","volume":"37","author":"H Moravvej","year":"2016","unstructured":"Moravvej H et al (2016) Comparison of the application of allogeneic fibroblast and autologous mesh grafting with the conventional method in the treatment of third-degree burns. J Burn Care Res 37(1):e90\u2013e95","journal-title":"J Burn Care Res"},{"issue":"5","key":"839_CR133","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.3390\/ijms23052850","volume":"23","author":"M Mousaei Ghasroldasht","year":"2022","unstructured":"Mousaei Ghasroldasht M et al (2022) Stem cell therapy: from idea to clinical practice. Int J Mol Sci 23(5):2850","journal-title":"Int J Mol Sci"},{"key":"839_CR134","doi-asserted-by":"crossref","unstructured":"Mullard A (2023) FDA approves first topical gene therapy. Nature reviews. Drug Discov","DOI":"10.1038\/d41573-023-00095-9"},{"issue":"1","key":"839_CR135","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1089\/hgtb.2012.180","volume":"24","author":"EM Murauer","year":"2013","unstructured":"Murauer EM et al (2013) A reporter-based screen to identify potent 3\u2019trans-splicing molecules for endogenous RNA repair. Hum Gene Ther Methods 24(1):19\u201327","journal-title":"Hum Gene Ther Methods"},{"key":"839_CR136","doi-asserted-by":"crossref","unstructured":"Murauer EM et al (2015) Advances in gene\/cell therapy in epidermolysis bullosa. Keio J Med:2014-0013-RE","DOI":"10.2302\/kjm.2014-0013-RE"},{"issue":"6","key":"839_CR137","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jaad.2009.06.011","volume":"61","author":"DF Murrell","year":"2009","unstructured":"Murrell DF (2009) Life with epidermolysis bullosa (EB): etiology, diagnosis, multidisciplinary care and therapy. J Am Acad Dermatol 61(6):1092\u20131093","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"839_CR138","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1038\/jid.2011.85","volume":"131","author":"N Nagy","year":"2011","unstructured":"Nagy N et al (2011) HB-EGF induces COL7A1 expression in keratinocytes and fibroblasts: possible mechanism underlying allogeneic fibroblast therapy in recessive dystrophic epidermolysis bullosa. J Investig Dermatol 131(8):1771\u20131774","journal-title":"J Investig Dermatol"},{"issue":"1","key":"839_CR139","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/bmb\/ldaa029","volume":"136","author":"G Naso","year":"2020","unstructured":"Naso G, Petrova A (2020) Cellular therapy options for genetic skin disorders with a focus on recessive dystrophic epidermolysis bullosa. Br Med Bull 136(1):30\u201345","journal-title":"Br Med Bull"},{"issue":"3","key":"839_CR140","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jdermsci.2021.11.004","volume":"104","author":"K Natsuga","year":"2021","unstructured":"Natsuga K et al (2021) Current topics in epidermolysis bullosa: pathophysiology and therapeutic challenges. J Dermatol Sci 104(3):164\u2013176","journal-title":"J Dermatol Sci"},{"issue":"4","key":"839_CR141","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3390\/bioengineering10040422","volume":"10","author":"A Niti","year":"2023","unstructured":"Niti A, Koliakos G, Michopoulou A (2023) Stem cell therapies for epidermolysis bullosa treatment. Bioengineering 10(4):422","journal-title":"Bioengineering"},{"issue":"1","key":"839_CR142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-019-1212-2","volume":"10","author":"A Nourian Dehkordi","year":"2019","unstructured":"Nourian Dehkordi A et al (2019) Skin tissue engineering: wound healing based on stem-cell-based therapeutic strategies. Stem Cell Res Ther 10(1):1\u201320","journal-title":"Stem Cell Res Ther"},{"key":"839_CR143","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.matbio.2017.12.010","volume":"71","author":"A Nystr\u00f6m","year":"2018","unstructured":"Nystr\u00f6m A, Bernasconi R, Bornert O (2018) Therapies for genetic extracellular matrix diseases of the skin. Matrix Biol 71:330\u2013347","journal-title":"Matrix Biol"},{"key":"839_CR144","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/978-1-62703-227-8_29","volume-title":"Molecular Dermatology","author":"A Nystr\u00f6m","year":"2013","unstructured":"Nystr\u00f6m A, Bruckner-Tuderman L, Kern JS (2013) Cell-and protein-based therapy approaches for epidermolysis bullosa. In: Molecular Dermatology. Springer, pp 425\u2013440"},{"issue":"9","key":"839_CR145","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.15252\/emmm.201505061","volume":"7","author":"A Nystr\u00f6m","year":"2015","unstructured":"Nystr\u00f6m A et al (2015) Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms. EMBO Mol Med 7(9):1211\u20131228","journal-title":"EMBO Mol Med"},{"issue":"10","key":"839_CR146","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.jid.2016.05.115","volume":"136","author":"MV Oever","year":"2016","unstructured":"Oever MV et al (2016) miR-29 regulates type VII collagen in recessive dystrophic epidermolysis bullosa. J Investig Dermatol 136(10):2013\u20132021","journal-title":"J Investig Dermatol"},{"issue":"4","key":"839_CR147","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2217\/pme-2018-0155","volume":"16","author":"KE Ormond","year":"2019","unstructured":"Ormond KE et al (2019) The clinical application of gene editing: ethical and social issues. Pers Med 16(4):337\u2013350","journal-title":"Pers Med"},{"issue":"2","key":"839_CR148","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jid.2019.07.701","volume":"140","author":"MJ Osborn","year":"2020","unstructured":"Osborn MJ et al (2020) Base editor correction of COL7A1 in recessive dystrophic epidermolysis bullosa patient-derived fibroblasts and iPSCs. J Investig Dermatol 140(2):338\u2013347","journal-title":"J Investig Dermatol"},{"issue":"6","key":"839_CR149","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3390\/diagnostics12061325","volume":"12","author":"M-C P\u00e2nzaru","year":"2022","unstructured":"P\u00e2nzaru M-C et al (2022) Epidermolysis bullosa\u2014a different genetic approach in correlation with genetic heterogeneity. Diagnostics 12(6):1325","journal-title":"Diagnostics"},{"issue":"02","key":"839_CR150","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/antib10020019","volume":"10","author":"PM Patel","year":"2021","unstructured":"Patel PM et al (2021) A review of acquired autoimmune blistering diseases in inherited epidermolysis bullosa: implications for the future of gene therapy. Antibodies 10(02):19","journal-title":"Antibodies"},{"issue":"17","key":"839_CR151","doi-asserted-by":"publisher","first-page":"10259","DOI":"10.1093\/nar\/gkx669","volume":"45","author":"P Peking","year":"2017","unstructured":"Peking P et al (2017) An RNA-targeted therapy for dystrophic epidermolysis bullosa. Nucleic Acids Res 45(17):10259\u201310269","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"839_CR152","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/bjd.17075","volume":"180","author":"P Peking","year":"2019","unstructured":"Peking P et al (2019) An ex vivo RNA trans-splicing strategy to correct human generalized severe epidermolysis bullosa simplex. Br J Dermatol 180(1):141\u2013148","journal-title":"Br J Dermatol"},{"issue":"5","key":"839_CR153","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/bjd.12599","volume":"169","author":"G Petrof","year":"2013","unstructured":"Petrof G et al (2013) Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial. Br J Dermatol 169(5):1025\u20131033","journal-title":"Br J Dermatol"},{"issue":"9","key":"839_CR154","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1038\/jid.2015.158","volume":"135","author":"G Petrof","year":"2015","unstructured":"Petrof G et al (2015) Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epidermolysis bullosa. J Invest Dermatol 135(9):2319","journal-title":"J Invest Dermatol"},{"issue":"5","key":"839_CR155","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/bjd.20958","volume":"186","author":"G Petrof","year":"2022","unstructured":"Petrof G et al (2022) The epidemiology of epidermolysis bullosa in England and Wales: data from the national epidermolysis bullosa database. Br J Dermatol 186(5):843\u2013848","journal-title":"Br J Dermatol"},{"issue":"6","key":"839_CR156","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/j.1365-2133.2010.09981.x","volume":"163","author":"A Petrova","year":"2010","unstructured":"Petrova A, Ilic D, McGrath J (2010) Stem cell therapies for recessive dystrophic epidermolysis bullosa. Br J Dermatol 163(6):1149\u20131156","journal-title":"Br J Dermatol"},{"issue":"1","key":"839_CR157","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.0022-202X.2004.23564.x","volume":"124","author":"E Pfendner","year":"2005","unstructured":"Pfendner E, Uitto J (2005) Plectin gene mutations can cause epidermolysis bullosa with pyloric atresia. J Investig Dermatol 124(1):111\u2013115","journal-title":"J Investig Dermatol"},{"key":"839_CR158","volume-title":"Junctional epidermolysis bullosa","author":"EG Pfendner","year":"2018","unstructured":"Pfendner, E.G. and A.W. Lucky, Junctional epidermolysis bullosa. 2018a."},{"key":"839_CR159","volume-title":"Dystrophic epidermolysis bullosa","author":"EG Pfendner","year":"2018","unstructured":"Pfendner, E.G. and A.W. Lucky, Dystrophic epidermolysis bullosa. 2018b."},{"issue":"22","key":"839_CR160","doi-asserted-by":"publisher","first-page":"8790","DOI":"10.3390\/ijms21228790","volume":"21","author":"M Piipponen","year":"2020","unstructured":"Piipponen M, Li D, Land\u00e9n NX (2020) The immune functions of keratinocytes in skin wound healing. Int J Mol Sci 21(22):8790","journal-title":"Int J Mol Sci"},{"issue":"6","key":"839_CR161","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.nbt.2012.04.002","volume":"29","author":"W Prasongchean","year":"2012","unstructured":"Prasongchean W, Ferretti (2012) Autologous stem cells for personalised medicine. New Biotechnol 29(6):641\u2013650","journal-title":"New Biotechnol"},{"issue":"10","key":"839_CR162","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/exd.13979","volume":"28","author":"C Prodinger","year":"2019","unstructured":"Prodinger C et al (2019) Epidermolysis bullosa: advances in research and treatment. Exp Dermatol 28(10):1176\u20131189","journal-title":"Exp Dermatol"},{"issue":"1","key":"839_CR163","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5582\/irdr.2017.01005","volume":"6","author":"E Rashidghamat","year":"2017","unstructured":"Rashidghamat E, McGrath JA (2017) Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa. Intractable Rare Dis Res 6(1):6\u201320","journal-title":"Intractable Rare Dis Res"},{"issue":"2","key":"839_CR164","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jaad.2019.11.038","volume":"83","author":"E Rashidghamat","year":"2020","unstructured":"Rashidghamat E et al (2020) Phase I\/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol 83(2):447\u2013454","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"839_CR165","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/mt.2008.234","volume":"17","author":"J Remington","year":"2009","unstructured":"Remington J et al (2009) Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa. Mol Ther 17(1):26\u201333","journal-title":"Mol Ther"},{"issue":"9","key":"839_CR166","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3390\/pharmaceutics14091973","volume":"14","author":"D Ren","year":"2022","unstructured":"Ren D et al (2022) Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy. Pharmaceutics 14(9):1973","journal-title":"Pharmaceutics"},{"issue":"3","key":"839_CR167","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0092-8674(75)80001-8","volume":"6","author":"JG Rheinwatd","year":"1975","unstructured":"Rheinwatd JG, Green H (1975) Seria cultivation of strains of human epidemal keratinocytes: the formation keratinizin colonies from single cell is. Cell 6(3):331\u2013343","journal-title":"Cell"},{"issue":"7","key":"839_CR168","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/stem.3356","volume":"39","author":"J Riedl","year":"2021","unstructured":"Riedl J et al (2021) ABCB5+ dermal mesenchymal stromal cells with favorable skin homing and local immunomodulation for recessive dystrophic epidermolysis bullosa treatment. Stem Cells 39(7):897\u2013903","journal-title":"Stem Cells"},{"issue":"1","key":"839_CR169","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0163-7258(98)00020-5","volume":"80","author":"PD Robbins","year":"1998","unstructured":"Robbins PD, Ghivizzani SC (1998) Viral vectors for gene therapy. Pharmacol Ther 80(1):35\u201347","journal-title":"Pharmacol Ther"},{"issue":"4","key":"839_CR170","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/jdv.17060","volume":"35","author":"S Rossi","year":"2021","unstructured":"Rossi S et al (2021) Immunofluorescence mapping, electron microscopy and genetics in the diagnosis and sub-classification of inherited epidermolysis bullosa: a single-centre retrospective comparative study of 87 cases with long-term follow-up. J Eur Acad Dermatol Venereol 35(4):1007\u20131016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"839_CR171","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/bjd.17648","volume":"180","author":"RB Saunderson","year":"2019","unstructured":"Saunderson RB et al (2019) A retrospective cohort study evaluating the accuracy of clinical diagnosis compared with immunofluorescence and electron microscopy in children with inherited epidermolysis bullosa. Br J Dermatol 180(5):1258\u20131259","journal-title":"Br J Dermatol"},{"key":"839_CR172","doi-asserted-by":"publisher","first-page":"120375","DOI":"10.1016\/j.lfs.2022.120375","volume":"294","author":"N Sayed","year":"2022","unstructured":"Sayed N et al (2022) Gene therapy: comprehensive overview and therapeutic applications. Life Sci 294:120375","journal-title":"Life Sci"},{"issue":"5","key":"839_CR173","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/bjd.13945","volume":"173","author":"A Schwieger-Briel","year":"2015","unstructured":"Schwieger-Briel A et al (2015) A COL7A1 variant leading to in-frame skipping of exon 15 attenuates disease severity in recessive dystrophic epidermolysis bullosa. Br J Dermatol 173(5):1308\u20131311","journal-title":"Br J Dermatol"},{"issue":"11","key":"839_CR174","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.tibs.2015.08.006","volume":"40","author":"A Sfeir","year":"2015","unstructured":"Sfeir A, Symington LS (2015) Microhomology-mediated end joining: a back-up survival mechanism or dedicated pathway? Trends Biochem Sci 40(11):701\u2013714","journal-title":"Trends Biochem Sci"},{"key":"839_CR175","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3389\/fgene.2019.00868","volume":"10","author":"A Shahryari","year":"2019","unstructured":"Shahryari A et al (2019) Development and clinical translation of approved gene therapy products for genetic disorders. Front Genet 10:868","journal-title":"Front Genet"},{"issue":"2","key":"839_CR176","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s11626-011-9478-4","volume":"48","author":"Y Shamis","year":"2012","unstructured":"Shamis Y et al (2012) iPSC-derived fibroblasts demonstrate augmented production and assembly of extracellular matrix proteins. In Vitro Cell Dev Biol Anim 48(2):112\u2013122","journal-title":"In Vitro Cell Dev Biol Anim"},{"issue":"4","key":"839_CR177","doi-asserted-by":"publisher","first-page":"e15028","DOI":"10.1111\/dth.15028","volume":"34","author":"F Shams","year":"2021","unstructured":"Shams F et al (2021) The utility of dermal fibroblasts in treatment of skin disorders: a paradigm of recessive dystrophic epidermolysis bullosa. Dermatol Ther 34(4):e15028","journal-title":"Dermatol Ther"},{"key":"839_CR178","doi-asserted-by":"publisher","first-page":"118932","DOI":"10.1016\/j.lfs.2020.118932","volume":"268","author":"P Sharma","year":"2021","unstructured":"Sharma P et al (2021) Stem cells and growth factors-based delivery approaches for chronic wound repair and regeneration: a promise to heal from within. Life Sci 268:118932","journal-title":"Life Sci"},{"key":"839_CR179","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2147\/CCID.S54681","volume":"8","author":"S Shinkuma","year":"2015","unstructured":"Shinkuma S (2015) Dystrophic epidermolysis bullosa: a review. Clin Cosmet Investig Dermatol 8:275","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"10","key":"839_CR180","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1089\/hum.2010.023","volume":"21","author":"Z Siprashvili","year":"2010","unstructured":"Siprashvili Z et al (2010) Long-term type VII collagen restoration to human epidermolysis bullosa skin tissue. Hum Gene Ther 21(10):1299\u20131310","journal-title":"Hum Gene Ther"},{"issue":"17","key":"839_CR181","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1001\/jama.2016.15588","volume":"316","author":"Z Siprashvili","year":"2016","unstructured":"Siprashvili Z et al (2016) Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa. Jama 316(17):1808\u20131817","journal-title":"Jama"},{"issue":"5 Suppl. 1","key":"839_CR182","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1016\/j.jid.2017.02.539","volume":"137","author":"Z Siprashvili","year":"2017","unstructured":"Siprashvili Z et al (2017) Phase I\/IIa clinical trial for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes. J Invest Dermatol 137(5 Suppl. 1):S89","journal-title":"J Invest Dermatol"},{"key":"839_CR183","doi-asserted-by":"crossref","unstructured":"Solis DC et al  Classification of two distinct wound types in recessive dystrophic epidermolysis bullosa: a retrospective and cohort natural history study. J Am Acad Dermatol 85(5):1296\u20131298","DOI":"10.1016\/j.jaad.2020.08.118"},{"issue":"1-2","key":"839_CR184","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000454919","volume":"58","author":"H Sorg","year":"2017","unstructured":"Sorg H et al (2017) Skin wound healing: an update on the current knowledge and concepts. Eur Surg Res 58(1-2):81\u201394","journal-title":"Eur Surg Res"},{"issue":"2","key":"839_CR185","first-page":"63","volume":"30","author":"A Stublar","year":"2021","unstructured":"Stublar A, Dragos V, Dolenc-Voljc M (2021) Inherited epidermolysis bullosa: epidemiology and patient care in Slovenia with a review of the updated classification. Acta Dermatovenerol Alp Panon Adriat 30(2):63\u201367","journal-title":"Acta Dermatovenerol Alp Panon Adriat"},{"issue":"6","key":"839_CR186","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1600-0625.2008.00721.x","volume":"17","author":"K Sugawara","year":"2008","unstructured":"Sugawara K et al (2008) Laminin-332 and-511 in skin. Exp Dermatol 17(6):473\u2013480","journal-title":"Exp Dermatol"},{"issue":"2","key":"839_CR187","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/bjd.13294","volume":"172","author":"T Takeichi","year":"2015","unstructured":"Takeichi T et al (2015) Founder mutation in dystonin-e underlying autosomal recessive epidermolysis bullosa simplex in Kuwait. Br J Dermatol 172(2):527\u2013531","journal-title":"Br J Dermatol"},{"issue":"11","key":"839_CR188","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1016\/j.jid.2016.07.004","volume":"136","author":"K Tamai","year":"2016","unstructured":"Tamai K, Uitto J (2016) Stem cell therapy for epidermolysis bullosa\u2014does it work? J Investig Dermatol 136(11):2119\u20132121","journal-title":"J Investig Dermatol"},{"issue":"16","key":"839_CR189","doi-asserted-by":"publisher","first-page":"6609","DOI":"10.1073\/pnas.1016753108","volume":"108","author":"K Tamai","year":"2011","unstructured":"Tamai K et al (2011) PDGFR\u03b1-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia. Proc Natl Acad Sci 108(16):6609\u20136614","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"839_CR190","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-021-01811-7","volume":"16","author":"JY Tang","year":"2021","unstructured":"Tang JY et al (2021) A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa. Orphanet J Rare Dis 16(1):1\u201325","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"839_CR191","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2340\/00015555-1063","volume":"91","author":"T Techanukul","year":"2011","unstructured":"Techanukul T et al (2011) Novel and recurrent FERMT1 gene mutations in Kindler syndrome. Acta Derm Venereol 91(3):267","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"839_CR192","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/14728214.2020.1839049","volume":"25","author":"M Titeux","year":"2020","unstructured":"Titeux M et al (2020) Emerging drugs for the treatment of epidermolysis bullosa. Expert Opin Emerg Drugs 25(4):467\u2013489","journal-title":"Expert Opin Emerg Drugs"},{"issue":"11","key":"839_CR193","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/gt.2016.57","volume":"23","author":"B Tockner","year":"2016","unstructured":"Tockner B et al (2016) Construction and validation of an RNA trans-splicing molecule suitable to repair a large number of COL7A1 mutations. Gene Ther 23(11):775\u2013784","journal-title":"Gene Ther"},{"issue":"6","key":"839_CR194","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/stem.647","volume":"29","author":"J Tolar","year":"2011","unstructured":"Tolar J, Blazar BR, Wagner JE (2011) Concise review: transplantation of human hematopoietic cells for extracellular matrix protein deficiency in epidermolysis bullosa. Stem Cells 29(6):900\u2013906","journal-title":"Stem Cells"},{"issue":"12","key":"839_CR195","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/exd.12014","volume":"21","author":"J Tolar","year":"2012","unstructured":"Tolar J, Wagner JE (2012) Management of severe epidermolysis bullosa by haematopoietic transplant: principles, perspectives and pitfalls. Exp Dermatol 21(12):896\u2013900","journal-title":"Exp Dermatol"},{"issue":"4","key":"839_CR196","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1056\/NEJMcibr1414709","volume":"372","author":"J Tolar","year":"2015","unstructured":"Tolar J, Wagner JE (2015) A biologic Velcro patch. N Engl J Med 372(4):382\u2013384","journal-title":"N Engl J Med"},{"issue":"5","key":"839_CR197","first-page":"1167","volume":"113","author":"J Tolar","year":"2009","unstructured":"Tolar J et al (2009) Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells. Blood, J Am Soc Hematol 113(5):1167\u20131174","journal-title":"Blood, J Am Soc Hematol"},{"key":"839_CR198","doi-asserted-by":"crossref","unstructured":"Tong Y, Zuo J, Yue D (2021) Application prospects of mesenchymal stem cell therapy for bronchopulmonary dysplasia and the challenges encountered. Biomed Res Int 2021","DOI":"10.1155\/2021\/9983664"},{"key":"839_CR199","doi-asserted-by":"crossref","unstructured":"Turczynski, S., et al., Antisense-mediated exon skipping to reframe transcripts. Exon Skipping: Methods and Protocols, 2012: 221-238.","DOI":"10.1007\/978-1-61779-767-5_15"},{"issue":"7","key":"839_CR200","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1038\/jid.2010.90","volume":"130","author":"J Uitto","year":"2010","unstructured":"Uitto J et al (2010) Progress in epidermolysis bullosa research: toward treatment and cure. J Investig Dermatol 130(7):1778\u20131784","journal-title":"J Investig Dermatol"},{"issue":"2","key":"839_CR201","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jid.2015.10.050","volume":"136","author":"J Uitto","year":"2016","unstructured":"Uitto J et al (2016) Progress toward treatment and cure of epidermolysis bullosa: summary of the DEBRA International Research Symposium EB2015. J Investig Dermatol 136(2):352\u2013358","journal-title":"J Investig Dermatol"},{"issue":"5","key":"839_CR202","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.jid.2017.12.016","volume":"138","author":"J Uitto","year":"2018","unstructured":"Uitto J et al (2018) EB2017\u2014progress in epidermolysis bullosa research toward treatment and cure. J Investig Dermatol 138(5):1010\u20131016","journal-title":"J Investig Dermatol"},{"issue":"3","key":"839_CR203","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jid.2016.10.023","volume":"137","author":"H Vahidnezhad","year":"2017","unstructured":"Vahidnezhad H et al (2017) Dystrophic epidermolysis bullosa: COL7A1 mutation landscape in a multi-ethnic cohort of 152 extended families with high degree of customary consanguineous marriages. J Investig Dermatol 137(3):660\u2013669","journal-title":"J Investig Dermatol"},{"issue":"3","key":"839_CR204","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.jid.2018.10.017","volume":"139","author":"H Vahidnezhad","year":"2019","unstructured":"Vahidnezhad H et al (2019) Phenotypic spectrum of epidermolysis bullosa: the paradigm of syndromic versus non-syndromic skin fragility disorders. J Investig Dermatol 139(3):522\u2013527","journal-title":"J Investig Dermatol"},{"issue":"1","key":"839_CR205","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/pr.2017.244","volume":"83","author":"M Vanden Oever","year":"2018","unstructured":"Vanden Oever M et al (2018) Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa. Pediatr Res 83(1):318\u2013324","journal-title":"Pediatr Res"},{"issue":"8","key":"839_CR206","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/stem.3022","volume":"37","author":"S Vander Beken","year":"2019","unstructured":"Vander Beken S et al (2019) Newly defined ATP-binding cassette subfamily B member 5 positive dermal mesenchymal stem cells promote healing of chronic iron-overload wounds via secretion of interleukin-1 receptor antagonist. Stem Cells 37(8):1057\u20131074","journal-title":"Stem Cells"},{"issue":"8","key":"839_CR207","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1136\/jmg.2005.039685","volume":"43","author":"R Varki","year":"2006","unstructured":"Varki R et al (2006) Epidermolysis bullosa. I. Molecular genetics of the junctional and hemidesmosomal variants. J Med Genet 43(8):641\u2013652","journal-title":"J Med Genet"},{"issue":"1","key":"839_CR208","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40001-020-00477-4","volume":"26","author":"\u017d Ve\u010deri\u0107-Haler","year":"2021","unstructured":"Ve\u010deri\u0107-Haler \u017d et al (2021) Multiorgan failure with fatal outcome after stem cell tourism. Eur J Med Res 26(1):1\u20135","journal-title":"Eur J Med Res"},{"issue":"6","key":"839_CR209","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.jaad.2013.08.014","volume":"69","author":"SS Venugopal","year":"2013","unstructured":"Venugopal SS et al (2013) A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol 69(6):898\u2013908","journal-title":"J Am Acad Dermatol"},{"key":"839_CR210","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/BF02331385","volume":"28","author":"I Virtanen","year":"1996","unstructured":"Virtanen I et al (1996) Laminin chains in the basement membranes of human thymus. Histochem J 28:643\u2013650","journal-title":"Histochem J"},{"issue":"3","key":"839_CR211","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.4049\/jimmunol.172.3.1397","volume":"172","author":"MN Vivinus-Nebot","year":"2004","unstructured":"Vivinus-Nebot MN et al (2004) Mature human thymocytes migrate on laminin-5 with activation of metalloproteinase-14 and cleavage of CD44. J Immunol 172(3):1397\u20131406","journal-title":"J Immunol"},{"issue":"7","key":"839_CR212","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa0910501","volume":"363","author":"JE Wagner","year":"2010","unstructured":"Wagner JE et al (2010) Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med 363(7):629\u2013639","journal-title":"N Engl J Med"},{"issue":"3","key":"839_CR213","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/sj.jid.5701152","volume":"128","author":"V Wally","year":"2008","unstructured":"Wally V et al (2008) 5\u2032 trans-splicing repair of the PLEC1 gene. J Investig Dermatol 128(3):568\u2013574","journal-title":"J Investig Dermatol"},{"key":"839_CR214","doi-asserted-by":"crossref","unstructured":"Wang R et al (2022) Novel variants in LAMA3 and COL7A1 and recurrent variant in KRT5 underlying epidermolysis bullosa in five Chinese families. Front Med:1\u20137","DOI":"10.1007\/s11684-021-0878-x"},{"key":"839_CR215","volume-title":"The roles of type VII collagen in wound healing and scar reduction","author":"X Wang","year":"2014","unstructured":"Wang X (2014) The roles of type VII collagen in wound healing and scar reduction. University of Southern California"},{"key":"839_CR216","doi-asserted-by":"crossref","unstructured":"Weber F et al (2001) Squamous cell carcinoma in junctional and dystrophic epidermolysis bullosa. Acta Derm Venereol 81(3)","DOI":"10.1080\/000155501750376285"},{"issue":"9","key":"839_CR217","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1038\/jid.2008.78","volume":"128","author":"T Wong","year":"2008","unstructured":"Wong T et al (2008) Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Investig Dermatol 128(9):2179\u20132189","journal-title":"J Investig Dermatol"},{"issue":"7","key":"839_CR218","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nm1063","volume":"10","author":"DT Woodley","year":"2004","unstructured":"Woodley DT et al (2004) Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat Med 10(7):693\u2013695","journal-title":"Nat Med"},{"issue":"3","key":"839_CR219","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/sj.mt.6300041","volume":"15","author":"DT Woodley","year":"2007","unstructured":"Woodley DT et al (2007) Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing. Mol Ther 15(3):628\u2013635","journal-title":"Mol Ther"},{"issue":"7","key":"839_CR220","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1038\/jid.2013.10","volume":"133","author":"DT Woodley","year":"2013","unstructured":"Woodley DT et al (2013) Intravenously injected recombinant human type VII collagen homes to skin wounds and restores skin integrity of dystrophic epidermolysis bullosa. J Invest Dermatol 133(7):1910","journal-title":"J Invest Dermatol"},{"key":"839_CR221","first-page":"242","volume":"15","author":"JT Wright","year":"1993","unstructured":"Wright JT, Fine J, Johnson L (1993) Hereditary epidermolysis bullosa: oral manifestations and dental management. Pediatr Dent 15:242\u2013242","journal-title":"Pediatr Dent"},{"issue":"1","key":"839_CR222","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.molmed.2008.11.005","volume":"15","author":"T-L Wu","year":"2009","unstructured":"Wu T-L, Ertl HC (2009) Immune barriers to successful gene therapy. Trends Mol Med 15(1):32\u201339","journal-title":"Trends Mol Med"},{"key":"839_CR223","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1111\/j.1524-475X.2007.00221.x","volume":"15","author":"Y Wu","year":"2007","unstructured":"Wu Y et al (2007) Bone marrow-derived stem cells in wound healing: a review. Wound Repair Regen 15:S18\u2013S26","journal-title":"Wound Repair Regen"},{"issue":"3","key":"839_CR224","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3109\/02844319509050129","volume":"29","author":"N Yamada","year":"1995","unstructured":"Yamada N, Shioya N, Kuroyanagi Y (1995) Evaluation of an allogeneic cultured dermal substitute composed of fibroblasts within a spongy collagen matrix as a wound dressing. Scand J Plast Reconstr Surg Hand Surg 29(3):211\u2013219","journal-title":"Scand J Plast Reconstr Surg Hand Surg"},{"issue":"5","key":"839_CR225","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/bjd.16797","volume":"179","author":"V Yenamandra","year":"2018","unstructured":"Yenamandra V et al (2018) Cardiomyopathy in patients with epidermolysis bullosa simplex with mutations in KLHL24. Br J Dermatol 179(5):1181\u20131183","journal-title":"Br J Dermatol"},{"key":"839_CR226","unstructured":"Youssefian, L., H. Vahidnezhad, and J. Uitto, Kindler syndrome synonym: congenital bullous poikiloderma. 2016, Seattle: Pagon RA, Adam MP, Ardinger HH, et al."},{"key":"839_CR227","volume-title":"Kindler syndrome","author":"L Youssefian","year":"2022","unstructured":"Youssefian, L., H. Vahidnezhad, and J. Uitto, Kindler syndrome. 2022."},{"issue":"5","key":"839_CR228","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1038\/jid.2015.9","volume":"135","author":"L Youssefian","year":"2015","unstructured":"Youssefian L et al (2015) The Kindler syndrome: a spectrum of FERMT1 mutations in Iranian families. J Invest Dermatol 135(5):1447\u20131450","journal-title":"J Invest Dermatol"},{"issue":"5","key":"839_CR229","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s11427-017-9057-2","volume":"60","author":"X Zhang","year":"2017","unstructured":"Zhang X et al (2017) CRISPR\/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy. Sci China Life Sci 60(5):468\u2013475","journal-title":"Sci China Life Sci"},{"issue":"1","key":"839_CR230","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/bjd.16139","volume":"179","author":"A Zidorio","year":"2018","unstructured":"Zidorio A et al (2018) Effectiveness of gastrostomy for improving nutritional status and quality of life in patients with epidermolysis bullosa: a systematic review. Br J Dermatol 179(1):42\u201349","journal-title":"Br J Dermatol"}],"container-title":["Journal of Applied Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13353-024-00839-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13353-024-00839-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13353-024-00839-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T15:11:03Z","timestamp":1731510663000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13353-024-00839-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,9]]},"references-count":230,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["839"],"URL":"https:\/\/doi.org\/10.1007\/s13353-024-00839-2","relation":{},"ISSN":["1234-1983","2190-3883"],"issn-type":[{"type":"print","value":"1234-1983"},{"type":"electronic","value":"2190-3883"}],"subject":[],"published":{"date-parts":[[2024,3,9]]},"assertion":[{"value":"26 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}